Steinbrecher, Daniela, Jebaraj, Billy Michael Chelliah, Schneider, Christof, Edelmann, Jennifer, Cymbalista, Florence, Leblond, Veronique, Delmer, Alain ORCID: 0000-0002-1430-2574, Ibach, Stefan, Tausch, Eugen, Scheffold, Annika, Bloehdorn, Johannes, Hallek, Michael, Dreger, Peter, Doehner, Hartmut and Stilgenbauer, Stephan (2018). Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome. Leuk. Lymphoma, 59 (7). S. 1614 - 1624. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Full text not available from this repository.

Abstract

Telomere length in chronic lymphocytic leukemia (CLL) is described as an independent prognostic factor based largely on previously untreated patients from chemotherapy based trials. Here, we studied telomere length associations in high-risk, relapsed/refractory CLL treated with alemtuzumab in the CLL2O study (n=110) of German and French CLL study groups. Telomere length (median 3.28kb, range 2.52-7.24kb) was relatively short, since 84.4% of patients had 17p- which is generally associated with short telomeres. Median telomere length was used for dichotomization into short and long telomere subgroups. Telomere length was associated with s-TK (p=.025) and TP53 mutations (p=.050) in untreated patients, while no association with clinical/biological characteristics was observed in relapsed/refractory CLL. Short telomeres had significant association with shorter PFS (p=.018) only in refractory CLL. Presence of short telomeres, loss of genes maintaining genomic integrity (SMC5) and increased incidence of chromothripsis, indicated the prevalence of genomic instability in this high-risk cohort (clinicaltrials.gov: NCT01392079).

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Steinbrecher, DanielaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Jebaraj, Billy Michael ChelliahUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schneider, ChristofUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Edelmann, JenniferUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Cymbalista, FlorenceUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Leblond, VeroniqueUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Delmer, AlainUNSPECIFIEDorcid.org/0000-0002-1430-2574UNSPECIFIED
Ibach, StefanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tausch, EugenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Scheffold, AnnikaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bloehdorn, JohannesUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hallek, MichaelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dreger, PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Doehner, HartmutUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Stilgenbauer, StephanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-200747
DOI: 10.1080/10428194.2017.1390236
Journal or Publication Title: Leuk. Lymphoma
Volume: 59
Number: 7
Page Range: S. 1614 - 1624
Date: 2018
Publisher: TAYLOR & FRANCIS LTD
Place of Publication: ABINGDON
ISSN: 1029-2403
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
GENE MUTATION STATUS; GENOMIC ABERRATIONS; TUMOR SUPPRESSION; CD38 EXPRESSION; TP53 MUTATIONS; CANCER-CELLS; DNA-DAMAGE; CLL; SURVIVAL; DYSFUNCTIONMultiple languages
Oncology; HematologyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/20074

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item